Illumina to Showcase Groundbreaking Genomics and Multiomics Innovations at ASHG Annual Meeting
Illumina, a leader in DNA sequencing and array technologies, is set to unveil a series of groundbreaking innovations in genomics and multiomics technologies at the American Society of Human Genetics (ASHG) Annual Meeting in Denver. The company will showcase its latest developments in whole-genome sequencing, proteomics, and single-cell technology, providing unparalleled insights into the complexities of human biology.
Revolutionizing Whole-Genome Sequencing with Constellation Mapped Read Technology:
Dr. Steve Barnard, Illumina’s Chief Technology Officer, will unveil details of the company’s revolutionary constellation mapped read technology, first announced in August 2024. This novel technology streamlines whole-genome workflows by eliminating traditional library prep and delivering the most complete whole genome yet.
Combining Illumina’s proven, highly accurate XLEAP-SBS chemistry with long-range information, this technology promises to resolve challenging genomic regions and generate ultra-long phased data with high-resolution insights into complex structural variation.
Dr. Niall Lennon, Chair and Chief Scientific Officer of Broad Clinical Labs, will present early data showcasing the flexibility and capabilities of this groundbreaking technology. Early access for the first product based on constellation mapped read technology is anticipated in the first half of 2025.
Introducing Illumina Protein Prep: A Complete NGS-Based Proteomics Solution:
Illumina will present updates on its Illumina Protein Prep solution, a complete next-generation sequencing (NGS)-based proteomics solution acquired through a partnership with Standard BioTools.
Illumina Protein Prep enables direct observation of cellular function through protein analysis, gaining insights into protein-driven disease traits. Its compatibility with NovaSeq X and NovaSeq 6000 Systems allows for multiomics analysis on a single platform – a key differentiator from existing proteomics methodologies.
Dr. Kamel Lahouel from Translational Genomics Research Institute (TGen) will discuss a pilot study exploring the potential of circulating protein concentrations as cancer biomarkers using Illumina Protein Prep. Early access for the solution is planned for early 2025, with an initial capacity to identify and quantify over 9000 human proteins.
Leading the Way in Single-Cell Analysis with Fluent PIPseq V:
Fluent BioSciences, an Illumina company, will showcase PIPseq V, its innovative single-cell analysis solution. Experts will discuss how PIPseq V enables researchers to delve deeper into the complexities of cell biology with a scalable and accessible solution.
Early access data and insights from a large study on more than one million neuronal single cells using PIPseq V will be shared.
Wide Range of Updates and Cutting-Edge Instruments:
In addition to these key innovations, Dr. Barnard’s presentation will also cover the latest updates on high-throughput 25B 100-cycle and 200-cycle kits for the NovaSeq X Series, set to be available by year-end.
Illumina’s new MiSeq i100 Series will be on display at booth 503 during the meeting, and the company will present five poster presentations and abstracts.
By innovative collaborations, strategic acquisitions, and relentlessly pushing the boundaries of technology, Illumina continues to forge the path for comprehensive, reliable, and accessible genomic insights, ultimately contributing to a deeper understanding of human health and disease.
Interview on Groundbreaking Innovations in Genomics: An Insight with Illumina’s Expert
Editor (Time.news): Welcome, Dr. Kam, and thank you for joining us today. There’s a lot of excitement around Illumina’s upcoming showcase at the ASHG Annual Meeting. Can you start by giving us a brief overview of what attendees can expect to see?
Dr. Kam: Thank you for having me! At this year’s ASHG Annual Meeting in Denver, we’re thrilled to present our latest advancements in genomics and multiomics technologies. Illumina’s innovations will provide attendees with unparalleled insights into human biology, specifically through our cutting-edge whole-genome sequencing, proteomics solutions, and single-cell technology.
Editor (Time.news): One of the highlights you mentioned is the revolutionary constellation mapped read technology. Could you elaborate on what makes this technology a game changer in whole-genome sequencing?
Dr. Kam: Absolutely! Constellation mapped read technology represents a significant leap forward in whole-genome sequencing by streamlining the workflow and eliminating traditional library preparation steps. This results in the most complete genome sequences available to date. By combining our highly accurate XLEAP-SBS chemistry with long-range genomic information, we’re able to resolve challenging areas within the genome and produce ultra-long phased data, offering high-resolution insights into complex structural variations in DNA.
Editor (Time.news): It sounds incredible! Can you share what the early data looks like from Dr. Niall Lennon’s presentations and what kind of results we can expect from this technology?
Dr. Kam: Indeed, Dr. Lennon will provide fascinating insights into the flexibility and capabilities of this new technology. The preliminary results are promising and suggest that researchers will soon have access to more complete and accurate genomic data than ever before. We anticipate that the first product based on this technology will be available in early 2025, which should greatly enhance our understanding of genomics in both research and clinical settings.
Editor (Time.news): That’s certainly something to look forward to. Moving to another exciting innovation, could you explain the Illumina Protein Prep and how it revolutionizes proteomics?
Dr. Kam: The Illumina Protein Prep is indeed a breakthrough in next-generation sequencing-based proteomics. This solution allows us to observe cellular functions directly through protein analysis, which can provide crucial insights into protein-driven disease traits. What sets our technology apart is that it is compatible with our NovaSeq X and NovaSeq 6000 Systems, facilitating multiomics analysis on a single platform unlike any existing methodologies. This integration simplifies the research process and opens up new avenues for exploration in human biology and disease.
Editor (Time.news): Multiomics seems to be a trend gaining momentum in genomics. How do you see this approach changing the landscape of genetic research?
Dr. Kam: Multiomics is indeed a vital trend. It enables researchers to not only look at genetic data but to integrate various layers of biological information—like genomics, proteomics, and transcriptomics—to paint a much more comprehensive picture of cellular activities and disease processes. This holistic view allows for more accurate diagnoses, targeted treatments, and personalized medicine, which could revolutionize how we approach health care and disease prevention in the future.
Editor (Time.news): Fascinating. As we wrap up, what do you hope researchers and professionals take away from Illumina’s presentations at the ASHG meeting?
Dr. Kam: Our ultimate goal is to inspire and empower researchers with our latest innovations. We hope that by showcasing how our technologies can simplify and enhance their research efforts, they will feel motivated to adopt these tools. We believe that accessibility to advanced genomic insights will accelerate discoveries and, ultimately, improve patient outcomes.
Editor (Time.news): Thank you, Dr. Kam, for sharing such enlightening insights about Illumina’s pivotal role in advancing genomics. We look forward to seeing the innovations you’ll showcase at the ASHG Annual Meeting!
Dr. Kam: Thank you! We’re excited to share these developments, and I look forward to engaging with the community at the event.